Dr. Robert Abouassaly is a urologist specializing in urologic oncology at Cleveland Clinic Abu Dhabi, United Arab Emirates. He serves as Institute Chief of the Integrated Surgical Institute and has a professional background in diagnosing and treating cancers affecting the urinary system and male reproductive organs. His clinical interests include prostate, kidney, bladder, testicular and other genitourinary cancers.

Urologic oncology combines specialist urological care with cancer diagnosis, surgical treatment and long-term follow-up. Patients may require assessment for urinary symptoms, abnormal imaging, raised prostate-specific antigen results, visible blood in the urine or a suspected tumour. The treatment approach depends on the type of cancer, its stage, the patient's health and the expected benefits and risks of available therapies.

Prostate cancer diagnosis and management

Prostate cancer is one of the common cancers affecting men. Some patients have no symptoms during the early stages, while others may experience urinary difficulties or other symptoms that require investigation. Urinary symptoms alone do not establish a diagnosis of cancer.

Evaluation may include medical history, physical examination, prostate-specific antigen testing, imaging and prostate biopsy when indicated. The results help clinicians determine whether cancer is present and assess its likely behaviour.

Treatment varies widely. Depending on cancer risk and patient circumstances, options may include active surveillance, surgery, radiation therapy, hormone therapy or other systemic treatments. Robotic-assisted prostatectomy may be considered for selected patients who are suitable for surgery. The decision should reflect disease characteristics, expected outcomes, possible side effects and the patient's preferences.

Kidney cancer assessment and surgery

Kidney tumours may be detected during imaging performed for unrelated reasons or following symptoms such as blood in the urine or persistent discomfort. Further evaluation helps establish the nature, location and extent of the tumour.

For selected small kidney tumours, partial nephrectomy may be considered to remove the affected portion while preserving as much healthy kidney tissue as possible. In other situations, complete removal of the kidney may be necessary. The choice depends on tumour size, location, kidney function, the condition of the opposite kidney and other clinical factors.

Surgical options may include minimally invasive or robotic techniques when appropriate. Patients should discuss the expected benefits, possible complications, kidney function after treatment and the need for surveillance following surgery.

Bladder and urinary tract cancers

Bladder cancer can present with visible or microscopic blood in the urine. Evaluation may include urine tests, imaging and examination of the bladder using a cystoscope. If a suspicious lesion is found, a procedure to obtain tissue may be required.

Treatment depends on whether the cancer is confined to the bladder lining or has invaded deeper tissues. Some patients can be treated with endoscopic removal and bladder-directed therapies, while more advanced disease may require major surgery and systemic treatment.

Careful follow-up is important because certain bladder cancers can recur. Patients should understand the recommended surveillance schedule, symptoms that need prompt attention and the purpose of any additional treatment.

Multidisciplinary cancer planning

Cancer management often requires collaboration between urologists, medical oncologists, radiation oncologists, radiologists and pathologists. Depending on the diagnosis, other specialists may also participate.

A multidisciplinary review can help clarify the diagnosis, compare treatment alternatives and coordinate care. Patients should ask how the proposed treatment is expected to affect cancer control, urinary function, sexual health, quality of life and recovery.

Where multiple reasonable options exist, a second opinion can help patients make an informed decision. The urgency of treatment and the value of additional review depend on the specific cancer and its clinical characteristics.

Qualifications and professional background

Dr. Abouassaly received his medical degree from McGill University in Canada, completed urology training at Cleveland Clinic and undertook a urologic oncology fellowship at the University of Toronto. He also holds a master's degree in clinical epidemiology and health services research. His official profile reports more than 150 peer-reviewed articles and lists 23 years of experience.

His academic and clinical background supports his profile as a specialist in urologic oncology. The hospital's current listing should be used to confirm his appointment availability and the services provided.

Care for international patients

Patients travelling to Abu Dhabi for cancer treatment should bring pathology reports, scans, biopsy results, previous surgical records, medication details and relevant laboratory tests. If treatment has already started, the dates and details of surgery, radiation or medication should also be supplied.

Before booking travel, patients should request a review of their records, an estimated treatment cost and a written plan covering hospital stay, recovery and follow-up. Some cancer treatments require repeated visits, so patients should establish how ongoing care can be coordinated after returning home.

Why consider Dr. Robert Abouassaly?

Dr. Abouassaly has a documented specialist background in urologic oncology, supported by formal training and research experience. His profile may be useful for patients seeking assessment of prostate, kidney or bladder cancers. Individual treatment recommendations must be made after clinical evaluation and review of diagnostic results.